AtonRa Partners’s Bicycle Therapeutics BCYC Stock Holding History

AtonRa Partners’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$189K	Sell	10,435 -1,153	-10%	-$19.1K	0.38%	112
2023 Q3	$233K	Sell	11,588 -2,631	-19%	-$60.2K	0.49%	104
2023 Q2	$363K	Sell	14,219 -950	-6%	-$22.1K	0.56%	80
2023 Q1	$323K	Sell	15,169 -1,898	-11%	-$47.6K	0.47%	97
2022 Q4	$505K	Sell	17,067 -4,527	-21%	-$121K	0.64%	69
2022 Q3	$502K	Sell	21,594 -1,425	-6%	-$33.9K	0.49%	86
2022 Q2	$386K	Buy	23,019 +6,394	+38%	+$135K	0.35%	112
2022 Q1	$730K	Buy	+16,625	New	+$776K	0.4%	92

Other funds holding BCYC

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

AtonRa Partners's BCYC Position: Q4 2023 in Review

AtonRa Partners reduced its Bicycle Therapeutics (BCYC) stake by 9.9% in Q4 2023, selling an estimated $19.1K and leaving 10,435 shares worth $189K. The position accounts for 0.38% of the portfolio, ranked #112.

AtonRa Partners first reported a position in BCYC in Q1 2022 and has held it in 8 quarters since. The position peaked at $730K in Q1 2022. 101 funds tracked by Wall St. Rank hold BCYC as of Q4 2023.

AtonRa Partners held 10,435 shares of Bicycle Therapeutics worth $189K as of Q4 2023.
AtonRa Partners sold 1,153 Bicycle Therapeutics shares in Q4 2023, an estimated $19.1K.
Bicycle Therapeutics made up 0.38% of AtonRa Partners's portfolio in Q4 2023, its #112 holding.
AtonRa Partners first reported a position in Bicycle Therapeutics in Q1 2022 and has held it in 8 quarters since.
AtonRa Partners's Bicycle Therapeutics position peaked at $730K in Q1 2022.
101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.